Login / Signup

Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis.

Lucia LaukováBarbora KonečnáBarbora VlkováVanda MlynárikováPeter CelecEmőke Šteňová
Published in: Rheumatology international (2018)
Treatment with bDMARDs decreases plasma ecDNA of both nuclear and mitochondrial origin. Dynamics of ecDNA is slower than dynamics of standard clinical markers. Therefore, it is likely to be not useful for monitoring of the disease progress, at least for RA.
Keyphrases
  • rheumatoid arthritis
  • circulating tumor
  • single molecule
  • cell free
  • combination therapy
  • systemic lupus erythematosus
  • interstitial lung disease
  • cell therapy